320 related articles for article (PubMed ID: 26399557)
1. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
[TBL] [Abstract][Full Text] [Related]
2. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
[TBL] [Abstract][Full Text] [Related]
3. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
4. Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans.
Hu ZY; Zhao YS; Wu D; Cheng ZN
Clin Chim Acta; 2009 Oct; 408(1-2):92-7. PubMed ID: 19654004
[TBL] [Abstract][Full Text] [Related]
5. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
[TBL] [Abstract][Full Text] [Related]
6. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
7. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu ZY; Zhao YS
Drug Metab Dispos; 2010 May; 38(5):817-23. PubMed ID: 20164111
[TBL] [Abstract][Full Text] [Related]
8. Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.
Lee J; Kim AH; Yi S; Lee S; Yoon SH; Yu KS; Jang IJ; Cho JY
AAPS J; 2017 Jul; 19(4):1196-1204. PubMed ID: 28523515
[TBL] [Abstract][Full Text] [Related]
9. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
10. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
[TBL] [Abstract][Full Text] [Related]
11. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
12. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD
Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393
[TBL] [Abstract][Full Text] [Related]
13. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
14. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Tahara H; Watanabe M; Hasegawa M
Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
[TBL] [Abstract][Full Text] [Related]
15. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V
Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
17. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
[TBL] [Abstract][Full Text] [Related]
18. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Dispos; 2013 Aug; 41(8):1488-93. PubMed ID: 23674608
[TBL] [Abstract][Full Text] [Related]
19. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
Dutreix C; Lorenzo S; Wang Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):915-20. PubMed ID: 24839948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
